Skip to main content
Clinical Trials/NCT02155595
NCT02155595
Completed
Not Applicable

Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy

Henry Ford Health System1 site in 1 country738 target enrollmentMay 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoporosis
Sponsor
Henry Ford Health System
Enrollment
738
Locations
1
Primary Endpoint
Prodromal bone deterioration (PBD)
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this protocol is to determine the risk of atypical femoral shaft (thigh bone) fractures after long term fracture prevention therapy with a class of drugs called "bisphosphonates", colloquially referred to as Alendronate, risedronate, Ibandronate, and Zoledronate.

In addition, the study is designed to find out which patient is most likely to develop this potential life changing complication and why. Finally, the results of this study will help clinicians to better understand the reason and thus tailor patient specific treatments...i.e., "the right treatment for the right patient for right duration."

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
August 31, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sudhaker D Rao, MD

Senior staff physician

Henry Ford Health System

Eligibility Criteria

Inclusion Criteria

  • women with a diagnosis of osteopenia or osteoporosis as defined by Bone Mineral density (BMD)
  • patient treated with BPs for \>5 years
  • patients treated with non-BP anti-fracture medications such as...
  • estrogens, raloxifene, calcitonin
  • treatment naive patients

Exclusion Criteria

  • all men regardless of BMD result
  • patients with obvious traumatic AFF
  • patients with normal BMD (better than -1.0 T-score at spine or proximal hip)
  • unable to take tetracycline
  • previous use of teriparatide
  • known allergies to the following:
  • tetracycline antibiotics
  • meperidine
  • midazolam

Outcomes

Primary Outcomes

Prodromal bone deterioration (PBD)

Time Frame: 5 years

Determine the prevalence of PBD and/or Atypical Femoral Fractures (AFF) in patients with post-menopausal or glucocorticoid related osteoporosis, either treated with bisphosphonate (BP) for more than 2 years or never treated with a BP

Secondary Outcomes

  • Diagnosis of PBD(5 years)

Study Sites (1)

Loading locations...

Similar Trials